Loading...
Browse all stories on DeepNewz
Visit
GSK Acquires Full Rights to Develop mRNA Flu and COVID-19 Vaccines from CureVac for €1.4 Billion
Jul 3, 2024, 07:27 AM
GSK and CureVac have restructured their collaboration into a new licensing agreement. As part of the deal, GSK will acquire full rights to develop and manufacture mRNA flu and COVID-19 shots from CureVac. The agreement includes a payment of up to €1.4 billion.
View original story
Markets
Yes • 50%
No • 50%
GSK financial reports and earnings releases
No • 50%
Yes • 50%
FDA official announcements and press releases
Yes • 50%
No • 50%
GSK official announcements and press releases
20-30% • 25%
<10% • 25%
10-20% • 25%
>30% • 25%
Market research reports and industry analysis
20-30% • 25%
>30% • 25%
<10% • 25%
10-20% • 25%
Market research reports and industry analysis
Flu vaccine • 33%
Other mRNA vaccines • 33%
COVID-19 vaccine • 33%
GSK financial reports and earnings releases